Here’s what to expect from diagnostics companies this year


by 5paisa Research Team Last Updated: Dec 16, 2022 - 10:50 am 12.3k Views

Diagnostic companies, which were rolling in with a surge in demand for testing, especially for Covid-19 RTPCR tests as also rapid tests during the last two years, are now bracing for a slowdown.

A sharp fall in Covid-19 and allied tests as the pandemic intensity wanes, coupled with growing preference for self-test kits, will lead to a 5-7% de-growth in revenue of diagnostics players this fiscal, according to rating and research agency CRISIL.

This is in contrast to a stellar 30% growth last fiscal driven by a severe second Covid wave and pent-up demand for regular tests.

At the same time, the decline in revenue along with higher operating expenses, largely marketing and advertisement related, will lead to moderation in operating margins to pre-pandemic levels of 24-25%, which is still healthy.

Last fiscal, higher realization from Covid allied tests and better operating leverage resulted in operating profitability reaching a decadal high of around 28%.

However, good cash generation, prudent capital spends (mainly on diagnostic equipment) and low debt levels will keep balance sheets at healthy levels, resulting in ‘stable’ credit profiles for diagnostic players.

CRISIL that looked at the numbers of nearly a dozen diagnostics players (including five pan-India players) that had aggregate revenue of over Rs 6,500 crore last fiscal indicates as much.

From about a fifth of the total last fiscal, the revenue share of Covid-19 tests has fallen to low-to-mid single-digit in the first half of this fiscal. Increasing preference for at-home tests will restrict revenue growth from Covid-19 lab tests in the remainder of this fiscal.

This shortfall is expected to be partly compensated by 12-14% increase in revenue contribution from regular tests in both existing geographies and from expansion into tier-2 and 3 cities.

Another trend being observed is increasing competition from online pharmacy players offering tests mainly in the wellness segment of regular tests. These online pharmacy players, without investing in physical infrastructure of their own, have tied up with regional labs for conducting such tests.

To counter this competition, established diagnostic players, who generate 10-12% of revenues from wellness tests, have stepped up investments in digital infrastructure and home-collection services. Additionally, they have increased marketing and advertisement spend to reinforce brand recall and awareness on quality. This is expected to shrink the opportunity for higher margins in the near term.

How do you rate this blog?


Start Investing in 5 mins*

Rs. 20 Flat Per Order | 0% Brokerage

About the Author

Our research team is composed of some highly qualified research professionals, their expertise range across sectors.

Open Free Demat Account
Resend OTP
Please Enter OTP
Account belongs to

By proceeding, you agree to the T&C.

Latest Blogs
Swing Trading Stocks: Week of 3 October 2023

Swing Trading Stocks for the Week

  • Sep 29, 2023
Weekly Outlook on Gold - 29 September 2023

Gold prices are facing sustained pressure despite a backdrop of dollar weakness, a rare occurrence that coincides with a decline in yields on US Treasuries. Typically, the strength of the dollar and higher yields have been key components of the Federal Reserve's hawkish monetary policy.

  • Sep 29, 2023
Weekly Market Outlook for 3 October to 6 October

The last week of September turned out to be volatile as the markets corrected during the monthly expiry to test the 19500 mark. We witnessed a strong recovery in Friday’s session, and the index finally ended the week above 19600, with marginally weekly loss.

  • Sep 29, 2023